nach oben

Journal of Endocrinological Investigation

Erschienen in:

24.06.2023 | Original Article

Combination of spironolactone and sitagliptin improves clinical outcomes of outpatients with COVID-19: a prospective cohort study

verfasst von: M. A. Davarpanah, R. Adatorwovor, Y. Mansoori, F. S. R. Ramsheh, A. Parsa, M. Hajiani, H. Faramarzi, R. Kavuluru, K. Asadipooya

Erschienen in: Journal of Endocrinological Investigation | Ausgabe 1/2024

Einloggen, um Zugang zu erhalten

Abstract

Background

There are evidences showing that sitagliptin and spironolactone can potentially improve the clinical outcomes of COVID-19 cases. In this observational study on acutely symptomatic outpatient COVID-19 cases, we investigated the effects of spironolactone and sitagliptin on the outcomes of the disease.

Methods

This is a prospective, naturally randomized cohort study. We followed mild to moderate symptomatic COVID-19 patients, who were treated with either combination (spironolactone 100 mg daily and sitagliptin 100 mg daily) or standard (steroid, antiviral and/or supportive care) therapy up to 30 days. The primary outcome was hospitalization rate. The secondary outcomes included ER visit, duration of disease, and complications, such as hypoglycemia, low blood pressure or altered mental status.

Results

Of the 206 patients referred to clinics randomly, 103 received standard therapy and 103 treated with combination therapy. There were no significant differences in baseline characteristics, except for slightly higher clinical score in control group (6.92 ± 4.01 control, 4.87 ± 2.92 combination; P < 0.0001). Treatment with combination therapy was associated with lower admission rate (5.8% combination, 22.3% control; P = 0.0011), ER visits (7.8% combination, 23.3% control; P = 0.0021) and average duration of symptoms (6.67 ± 2.30 days combination, 18.71 ± 6.49 days control; P ≤ 0.0001).

Conclusions

The combination of sitagliptin and spironolactone reduced duration of COVID infection and hospital visits better than standard therapeutic approaches in outpatients with COVID-19. The effects of combination of sitagliptin and spironolactone in COVID-19 patients should be further verified in a double-blind, randomized, placebo-controlled trial.

Nur mit Berechtigung zugänglich

Hopkins J (2020) Coronavirus resource center. Im Internet (Stand: 1904 2020). https://coronavirus.jhu.edu/map.html

Gao YD, Ding M, Dong X, Zhang JJ, KursatAzkur A, Azkur D, Gan H, Sun YL, Fu W, Li W, Liang HL, Cao YY, Yan Q, Cao C, Gao HY, Brüggen MC, van de Veen W, Sokolowska M, Akdis M, Akdis CA (2021) Risk factors for severe and critically ill COVID-19 patients: a review. Allergy 76(2):428–455PubMedCrossRef

Christie A, Henley SJ, Mattocks L, Fernando R, Lansky A, Ahmad FB, Adjemian J, Anderson RN, Binder AM, Carey K, Dee DL, Dias T, Duck WM, Gaughan DM, Lyons BC, McNaghten AD, Park MM, Reses H, Rodgers L, Van Santen K, Walker D, Beach MJ (2021) Decreases in COVID-19 cases, emergency department visits, hospital admissions, and deaths among older adults following the introduction of COVID-19 vaccine—United States, September 6, 2020-May 1, 2021. MMWR Morb Mortal Wkly Rep 70(23):858–864PubMedPubMedCentralCrossRef

Kustin T, Harel N, Finkel U, Perchik S, Harari S, Tahor M, Caspi I, Levy R, Leshchinsky M, Ken Dror S, Bergerzon G, Gadban H, Gadban F, Eliassian E, Shimron O, Saleh L, Ben-Zvi H, Keren Taraday E, Amichay D, Ben-Dor A, Sagas D, Strauss M, Shemer Avni Y, Huppert A, Kepten E, Balicer RD, Netzer D, Ben-Shachar S, Stern A (2021) Evidence for increased breakthrough rates of SARS-CoV-2 variants of concern in BNT162b2-mRNA-vaccinated individuals. Nat Med 20(1):236

Xie J, Wang Z, Liang J, Lin H, Yang Z, Wang Y, Liang H, Wu H, Chen R, Ou Y, Wang F, Wang Y, Wang Y, Luo W, Zhang J, Li N, Li Z, Jiang M, Li S, Li J (2021) Critical review of the scientific evidence and recommendations in COVID-19 management guidelines. Open Forum Infect Dis 8(8):ofab376PubMedPubMedCentralCrossRef

Weinreich DM, Sivapalasingam S, Norton T, Ali S, Gao H, Bhore R, Xiao J, Hooper AT, Hamilton JD, Musser BJ, Rofail D, Hussein M, Im J, Atmodjo DY, Perry C, Pan C, Mahmood A, Hosain R, Davis JD, Turner KC, Baum A, Kyratsous CA, Kim Y, Cook A, Kampman W, Roque-Guerrero L, Acloque G, Aazami H, Cannon K, Simón-Campos JA, Bocchini JA, Kowal B, DiCioccio AT, Soo Y, Geba GP, Stahl N, Lipsich L, Braunstein N, Herman G, Yancopoulos GD (2021) REGEN-COV antibody combination and outcomes in outpatients with Covid-19. New Eng J Med

Harvey WT, Carabelli AM, Jackson B, Gupta RK, Thomson EC, Harrison EM, Ludden C, Reeve R, Rambaut A, Peacock SJ, Robertson DL (2021) SARS-CoV-2 variants, spike mutations and immune escape. Nat Rev Microbiol 19(7):409–424PubMedPubMedCentralCrossRef

Chen RE, Zhang X, Case JB, Winkler ES, Liu Y, VanBlargan LA, Liu J, Errico JM, Xie X, Suryadevara N, Gilchuk P, Zost SJ, Tahan S, Droit L, Turner JS, Kim W, Schmitz AJ, Thapa M, Wang D, Boon ACM, Presti RM, O’Halloran JA, Kim AHJ, Deepak P, Pinto D, Fremont DH, Crowe JE Jr, Corti D, Virgin HW, Ellebedy AH, Shi PY, Diamond MS (2021) Resistance of SARS-CoV-2 variants to neutralization by monoclonal and serum-derived polyclonal antibodies. Nat Med 27(4):717–726PubMedPubMedCentralCrossRef

Walls AC, Park YJ, Tortorici MA, Wall A, McGuire AT, Veesler D (2020) Structure, function, and antigenicity of the SARS-CoV-2 spike glycoprotein. Cell

10.

Vankadari N, Wilce JA (2020) Emerging WuHan (COVID-19) coronavirus: glycan shield and structure prediction of spike glycoprotein and its interaction with human CD26. Emerg Microbes Infect 9(1):601–604PubMedPubMedCentralCrossRef

11.

Wrapp D, Wang N, Corbett KS, Goldsmith JA, Hsieh CL, Abiona O, Graham BS, McLellan JS (2020) Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation. Science (New York, NY) 367(6483):1260–1263CrossRef

12.

Zipeto D, Palmeira JDF, Argañaraz GA, Argañaraz ER (2020) ACE2/ADAM17/TMPRSS2 interplay may be the main risk factor for COVID-19. Front Immunol 11:576745PubMedPubMedCentralCrossRef

13.

Yeung ML, Teng JLL, Jia L, Zhang C, Huang C, Cai JP, Zhou R, Chan KH, Zhao H, Zhu L, Siu KL, Fung SY, Yung S, Chan TM, To KK, Chan JF, Cai Z, Lau SKP, Chen Z, Jin DY, Woo PCY, Yuen KY (2021) Soluble ACE2-mediated cell entry of SARS-CoV-2 via interaction with proteins related to the renin-angiotensin system. Cell 184(8):2212-2228.e2212PubMedPubMedCentralCrossRef

14.

Wilcox CS, Pitt B (2020) Is spironolactone the preferred renin-angiotensin-aldosterone inhibitor for protection against COVID-19? J Cardiovasc Pharmacol 77(3):323–331PubMedCrossRef

15.

Satoh M, Ishikawa Y, Minami Y, Akatsu T, Nakamura M (2006) Eplerenone inhibits tumour necrosis factor alpha shedding process by tumour necrosis factor alpha converting enzyme in monocytes from patients with congestive heart failure. Heart 92(7):979–980PubMedPubMedCentralCrossRef

16.

Dong D, Fan TT, Ji YS, Yu JY, Wu S, Zhang L (2019) Spironolactone alleviates diabetic nephropathy through promoting autophagy in podocytes. Int Urol Nephrol 51(4):755–764PubMedPubMedCentralCrossRef

17.

Keidar S, Gamliel-Lazarovich A, Kaplan M, Pavlotzky E, Hamoud S, Hayek T, Karry R, Abassi Z (2005) Mineralocorticoid receptor blocker increases angiotensin-converting enzyme 2 activity in congestive heart failure patients. Circ Res 97(9):946–953PubMedCrossRef

18.

Rakhmat II, Kusmala YY, Handayani DR, Juliastuti H, Nawangsih EN, Wibowo A, Lim MA, Pranata R (2021) Dipeptidyl peptidase-4 (DPP-4) inhibitor and mortality in coronavirus disease 2019 (COVID-19)—a systematic review, meta-analysis, and meta-regression. Diabet Metab Syndrome 15(3):777–782CrossRef

19.

Abbasi F, Adatorwovor R, Davarpanah MA, Mansoori Y, Hajiani M, Azodi F, Sefidbakht S, Davoudi S, Rezaei F, Mohammadmoradi S, Asadipooya K (2022) A randomized trial of sitagliptin and spironolactone with combination therapy in hospitalized adults with COVID-19. J Endocr Soc 6(4):bvac017PubMedPubMedCentralCrossRef

20.

Rahimi F, TalebiBezmin Abadi A (2021) Emergence of the delta plus variant of SARS-CoV-2 in Iran. Gene Reports 25:101341PubMedPubMedCentralCrossRef

21.

Garcia M, Lipskiy N, Tyson J, Watkins R, Esser ES, Kinley T (2020) Centers for Disease Control and Prevention 2019 novel coronavirus disease (COVID-19) information management: addressing national health-care and public health needs for standardized data definitions and codified vocabulary for data exchange. J Am Med Inform Assoc 27(9):1476–1487PubMedPubMedCentralCrossRef

22.

Blair JE, Gotimukul A, Wang F, Mina SA, Bartels HC, Burns MW, Kole AE, Vikram HR, Gea-Banacloche JC, Seville MT, Petty SAB, Vikram A, Orenstein R (2021) Mild to moderate COVID-19 illness in adult outpatients: characteristics, symptoms, and outcomes in the first 4 weeks of illness. Medicine 100(24):e26371PubMedPubMedCentralCrossRef

23.

Rahmanzade R, Rahmanzadeh R, Hashemian SM, Tabarsi P (2020) Iran’s approach to COVID-19: evolving treatment protocols and ongoing clinical trials. Front Public Health 8:551889PubMedPubMedCentralCrossRef

24.

Goodacre S, Thomas B, Sutton L, Burnsall M, Lee E, Bradburn M, Loban A, Waterhouse S, Simmonds R, Biggs K, Marincowitz C, Schutter J, Connelly S, Sheldon E, Hall J, Young E, Bentley A, Challen K, Fitzsimmons C, Harris T, Lecky F, Lee A, Maconochie I, Walter D (2021) Derivation and validation of a clinical severity score for acutely ill adults with suspected COVID-19: the PRIEST observational cohort study. PLoS One 16(1):e0245840PubMedPubMedCentralCrossRef

25.

Tsang HF, Chan LWC, Cho WCS, Yu ACS, Yim AKY, Chan AKC, Ng LPW, Wong YKE, Pei XM, Li MJW, Wong SC (2021) An update on COVID-19 pandemic: the epidemiology, pathogenesis, prevention and treatment strategies. Expert Rev Anti Infect Ther 19(7):877–888PubMedCrossRef

26.

Peacocke EF, Heupink LF, Frønsdal K, Dahl EH, Chola L (2021) Global access to COVID-19 vaccines: a scoping review of factors that may influence equitable access for low and middle-income countries. BMJ Open 11(9):e049505PubMedCrossRef

27.

McCullough PA, Kelly RJ, Ruocco G, Lerma E, Tumlin J, Wheelan KR, Katz N, Lepor NE, Vijay K, Carter H, Singh B, McCullough SP, Bhambi BK, Palazzuoli A, De Ferrari GM, Milligan GP, Safder T, Tecson KM, Wang DD, McKinnon JE, O’Neill WW, Zervos M, Risch HA (2021) Pathophysiological basis and rationale for early outpatient treatment of SARS-CoV-2 (COVID-19) infection. Am J Med 134(1):16–22PubMedCrossRef

28.

Lee TC, Bortolussi-Courval É, Belga S, Daneman N, Chan AK, Hanula R, Ezer N, McDonald EG (2022) Inhaled corticosteroids for outpatients with Covid-19: a meta-analysis. Eur Respir J 9:763

29.

Jayk Bernal A, Gomes da Silva MM, Musungaie DB, Kovalchuk E, Gonzalez A, Delos Reyes V, Martín-Quirós A, Caraco Y, Williams-Diaz A, Brown ML, Du J, Pedley A, Assaid C, Strizki J, Grobler JA, Shamsuddin HH, Tipping R, Wan H, Paschke A, Butterton JR, Johnson MG, De Anda C (2022) Molnupiravir for oral treatment of Covid-19 in nonhospitalized patients. New Eng J Med 386(6):509–520PubMedCrossRef

30.

Hammond J, Leister-Tebbe H, Gardner A, Abreu P, Bao W, Wisemandle W, Baniecki M, Hendrick VM, Damle B, Simón-Campos A, Pypstra R, Rusnak JM (2022) Oral Nirmatrelvir for high-risk, nonhospitalized adults with Covid-19. N Engl J Med 386(15):1397–1408PubMedCrossRef

31.

Gottlieb RL, Vaca CE, Paredes R, Mera J, Webb BJ, Perez G, Oguchi G, Ryan P, Nielsen BU, Brown M, Hidalgo A, Sachdeva Y, Mittal S, Osiyemi O, Skarbinski J, Juneja K, Hyland RH, Osinusi A, Chen S, Camus G, Abdelghany M, Davies S, Behenna-Renton N, Duff F, Marty FM, Katz MJ, Ginde AA, Brown SM, Schiffer JT, Hill JA (2022) Early remdesivir to prevent progression to severe Covid-19 in outpatients. N Engl J Med 386(4):305–315PubMedCrossRef

32.

Mahase E (2021) Covid-19: Pfizer’s paxlovid is 89% effective in patients at risk of serious illness, company reports. British Medical Journal Publishing Group

33.

Lin WT, Hung SH, Lai CC, Wang CY, Chen CH (2022) The impact of neutralizing monoclonal antibodies on the outcomes of COVID-19 outpatients: a systematic review and meta-analysis of randomized controlled trials. J Med Virol 94(5):2222–2229PubMedPubMedCentralCrossRef

34.

Coulson JM, Adams A, Gray LA, Evans A (2022) COVID-19 "Rebound" associated with nirmatrelvir/ritonavir pre-hospital therapy. J Infect 85(4):436–480

35.

Vitiello A (2022) Sars-Cov-2 and risk of antiviral drug resistance. Ir J Med Sci 191(5):2367–2368PubMedCrossRef

36.

Komorowski A, Tseng A, Vandersluis S (2022) Evidence-based recommendations on the use of nirmatrelvir/ritonavir (Paxlovid) for adults in Ontario. Sci Brief Ontario COVID-19 Sci Advisory Table 3:57

37.

Usher AD (2022) The global COVID-19 treatment divide. Lancet (London, England) 399(10327):779–782PubMedCrossRef

38.

Saravolatz LD, Depcinski S, Sharma M (2023) Molnupiravir and nirmatrelvir-ritonavir: oral coronavirus disease 2019 antiviral drugs. Clin Infect Dis 76(1):165–171PubMedCrossRef

39.

Monteil V, Kwon H, Prado P, Hagelkrüys A, Wimmer RA, Stahl M, Leopoldi A, Garreta E, Hurtado Del Pozo C, Prosper F, Romero JP, Wirnsberger G, Zhang H, Slutsky AS, Conder R, Montserrat N, Mirazimi A, Penninger JM (2020) Inhibition of SARS-CoV-2 infections in engineered human tissues using clinical-grade soluble human ACE2. Cell 181(4):905-913.e907PubMedPubMedCentralCrossRef

40.

Wysocki J, Ye M, Hassler L, Gupta AK, Wang Y, Nicoleascu V, Randall G, Wertheim JA, Batlle D (2021) A novel soluble ACE2 variant with prolonged duration of action neutralizes SARS-CoV-2 infection in human kidney organoids. J Am Soc Nephrol 32(4):795–803PubMedPubMedCentralCrossRef

41.

Xu J, Xu X, Jiang L, Dua K, Hansbro PM, Liu G (2020) SARS-CoV-2 induces transcriptional signatures in human lung epithelial cells that promote lung fibrosis. Respir Res 21(1):182PubMedPubMedCentralCrossRef

42.

Angeli F, Zappa M, Reboldi G, Trapasso M, Cavallini C, Spanevello A, Verdecchia P (2021) The pivotal link between ACE2 deficiency and SARS-CoV-2 infection: one year later. Eur J Intern Med 93:28–34

43.

Jeon D, Son M, Choi J (2021) Effect of spironolactone on COVID-19 in patients with underlying liver cirrhosis: a nationwide case-control study in South Korea. Front Med 8:629176CrossRef

44.

Mareev VY, Orlova YA, Plisyk AG, Pavlikova EP, Matskeplishvili ST, Akopyan ZA, Seredenina EM, Potapenko AV, Agapov MA, Asratyan DA, Dyachuk LI, Samokhodskaya LM, Mershina E, Sinitsyn VE, Pakhomov PV, Bulanova MM, Fuks AA, Mareev YV, Begrambekova YL, Kamalov A (2020) results of open-label non-randomized comparative clinical trial: “bromhexine and spironolactone for coronavirus infection requiring hospitalization” (BISCUIT). Kardiologiia 60(11):4–15PubMedCrossRef

45.

Jackson CB, Farzan M, Chen B, Choe H (2022) Mechanisms of SARS-CoV-2 entry into cells. Nat Rev Mol Cell Biol 23(1):3–20PubMedCrossRef

46.

Synowiec A, Szczepański A, Barreto-Duran E, Lie LK, Pyrc K (2021) Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2): a systemic infection. Clin Microbiol Rev 34(2):e00133–e00120

47.

Solerte SB, Di Sabatino A, Galli M, Fiorina P (2020) Dipeptidyl peptidase-4 (DPP4) inhibition in COVID-19. Acta Diabetol 57(7):779–783PubMedPubMedCentralCrossRef

48.

Bakhtiari M, Asadipooya K (2022) Metainflammation in COVID-19. Endocr Metab Immune Disord Drug Targets 22(12):1154–1166

49.

Ben Nasr M, D’Addio F, Montefusco L, Usuelli V, Loretelli C, Rossi A, Pastore I, Abdelsalam A, Maestroni A, Dell’Acqua M, Ippolito E, Assi E, Seelam AJ, Fiorina RM, Chebat E, Morpurgo P, Lunati ME, Bolla AM, Abdi R, Bonventre JV, Rusconi S, Riva A, Corradi D, Santus P, Clark P, Nebuloni M, Baldi G, Finzi G, Folli F, Zuccotti GV, Galli M, Herold KC, Fiorina P (2022) Indirect and direct effects of SARS-CoV-2 on human pancreatic islets. Diabetes 71(7):1579–1590PubMedPubMedCentralCrossRef

50.

Müller JA, Groß R, Conzelmann C, Krüger J, Merle U, Steinhart J, Weil T, Koepke L, Bozzo CP, Read C, Fois G, Eiseler T, Gehrmann J, van Vuuren J, Wessbecher IM, Frick M, Costa IG, Breunig M, Grüner B, Peters L, Schuster M, Liebau S, Seufferlein T, Stenger S, Stenzinger A, MacDonald PE, Kirchhoff F, Sparrer KMJ, Walther P, Lickert H, Barth TFE, Wagner M, Münch J, Heller S, Kleger A (2021) SARS-CoV-2 infects and replicates in cells of the human endocrine and exocrine pancreas. Nat Metab 3(2):149–165PubMedCrossRef

51.

Montefusco L, Ben Nasr M, D’Addio F, Loretelli C, Rossi A, Pastore I, Daniele G, Abdelsalam A, Maestroni A, Dell’Acqua M, Ippolito E, Assi E, Usuelli V, Seelam AJ, Fiorina RM, Chebat E, Morpurgo P, Lunati ME, Bolla AM, Finzi G, Abdi R, Bonventre JV, Rusconi S, Riva A, Corradi D, Santus P, Nebuloni M, Folli F, Zuccotti GV, Galli M, Fiorina P (2021) Acute and long-term disruption of glycometabolic control after SARS-CoV-2 infection. Nat Metab 3(6):774–785PubMedPubMedCentralCrossRef

52.

Loretelli C, Abdelsalam A, D'Addio F, Ben Nasr M, Assi E, Usuelli V, Maestroni A, Seelam AJ, Ippolito E, Di Maggio S, Loreggian L, Radovanovic D, Vanetti C, Yang J, El Essawy B, Rossi A, Pastore I, Montefusco L, Lunati ME, Bolla AM, Biasin M, Antinori S, Santus P, Riva A, Zuccotti GV, Galli M, Rusconi S, Fiorina P (2021) PD-1 blockade counteracts post-COVID-19 immune abnormalities and stimulates the anti-SARS-CoV-2 immune response. JCI Insight 6(24):e146701

53.

Asadipooya K (2022) Letter to the editor from Asadipooya: “obesity and COVID-19: mechanistic insights from adipose tissue”. J Clin Endocrinol Metab 107(10):e4269

54.

Davarpanah MA, Adatorwovor R, Mansoori Y, Ramsheh FSR, Parsa A, Hajiani M, Faramarzi H, Kavuluru R, Asadipooya K (2022) Combination of spironolactone and sitagliptin improves clinical outcomes of outpatients with COVID-19: a prospective cohort study. medRxiv. 2022.2001.2021.22269322

55.

Deacon CF (2020) Dipeptidyl peptidase 4 inhibitors in the treatment of type 2 diabetes mellitus. Nat Rev Endocrinol 16(11):642–653PubMedCrossRef

56.

Stoian AP, Sachinidis A, Stoica RA, Nikolic D, Patti AM, Rizvi AA (2020) The efficacy and safety of dipeptidyl peptidase-4 inhibitors compared to other oral glucose-lowering medications in the treatment of type 2 diabetes. Metabolism 109:154295PubMedCrossRef

57.

Martin KA, Anderson RR, Chang RJ, Ehrmann DA, Lobo RA, Murad MH, Pugeat MM, Rosenfield RL (2018) Evaluation and treatment of hirsutism in premenopausal women: an endocrine society clinical practice guideline. J Clin Endocrinol Metab 103(4):1233–1257PubMedCrossRef

Titel: Combination of spironolactone and sitagliptin improves clinical outcomes of outpatients with COVID-19: a prospective cohort study
verfasst von: M. A. Davarpanah
R. Adatorwovor
Y. Mansoori
F. S. R. Ramsheh
A. Parsa
M. Hajiani
H. Faramarzi
R. Kavuluru
K. Asadipooya
Publikationsdatum: 24.06.2023
Verlag: Springer International Publishing
Erschienen in: Journal of Endocrinological Investigation / Ausgabe 1/2024
Elektronische ISSN: 1720-8386
DOI: https://doi.org/10.1007/s40618-023-02141-0

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

Hypertherme Chemotherapie bietet Chance auf Blasenerhalt

07.05.2024 Harnblasenkarzinom Nachrichten

Eine hypertherme intravesikale Chemotherapie mit Mitomycin kann für Patienten mit hochriskantem nicht muskelinvasivem Blasenkrebs eine Alternative zur radikalen Zystektomie darstellen. Kölner Urologen berichten über ihre Erfahrungen.

Vorhofflimmern bei Jüngeren gefährlicher als gedacht

06.05.2024 Vorhofflimmern Nachrichten

Immer mehr jüngere Menschen leiden unter Vorhofflimmern. Betroffene unter 65 Jahren haben viele Risikofaktoren und ein signifikant erhöhtes Sterberisiko verglichen mit Gleichaltrigen ohne die Erkrankung.

Chronisches Koronarsyndrom: Gefahr von Hospitalisierung wegen Herzinsuffizienz

06.05.2024 Herzinsuffizienz Nachrichten

Obwohl ein rezidivierender Herzinfarkt bei chronischem Koronarsyndrom wahrscheinlich die Hauptsorge sowohl der Patienten als auch der Ärzte ist, sind andere Ereignisse womöglich gefährlicher. Laut einer französischen Studie stellt eine Hospitalisation wegen Herzinsuffizienz eine größere Gefahr dar.

„Restriktion auf vier Wochen Therapie bei Schlaflosigkeit ist absurd!“

06.05.2024 Insomnie Nachrichten

Chronische Insomnie als eigenständiges Krankheitsbild ernst nehmen und adäquat nach dem aktuellen Forschungsstand behandeln: Das forderte der Schlafmediziner Dr. Dieter Kunz von der Berliner Charité beim Praxis Update.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Live-Webinar "Chronische Unterbauch- und Viszeralschmerzen in der Praxis managen"

Springer Medizin

Abstract

Background

Methods

Results

Conclusions

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 1/2024

Micro-scale vertebral features in postmenopausal women with alcohol-associated and metabolic-associated fatty liver disease: ex vivo bone quality analyses

Outcome of brain metastases from adrenocortical carcinoma: a pooled analysis

Genotype–phenotype relationship and comparison between eastern and western patients with osteogenesis imperfecta

Development and validation of survival nomograms for patients with differentiated thyroid cancer with distant metastases: a SEER Program-based study

Long-acting somatostatin analogs and well differentiated neuroendocrine tumors: a 20-year-old story